RePORT China consortium joined RePORT International in January 2017 after signing the RePORT International Memorandum of Understanding and followed the bylaws, which set clear guidelines and expectations for current and future groups to work together on a broad set of common goals.; China consortium developed a locally- tailored study protocol, manual of laboratory operations and case report forms (CRFs) for qualified cases enrollment, sample collection and storage, data collection and sharing based on the Common Protocol and biorepository standards by RePORT International. 7 sites (Beijing, Changsha, Fuzhou, Shanghai, Suzhou, Jingzhou and Zhenjiang) of RePORT China kept active contribution to the sample and data pool.180 eligilble participants set as the target for RePROT-China has achieved with the number of samples origin from blood, urine and sputum at 2446. The consortium aims to facilitate intra- and inter-consortium cooperation and research. Since 2019, RePORT China consortium has cooperated with other RePORT consortia members to do cross-consortium research. The topics of the two multi-consortium studies were "Dynamic detection of cytokines by liquid chip technology to evaluate the efficacy of anti-tuberculosis treatment" and "Pharmacokinetic Assessment of MDR-TB Drugs in the Treatment of TB Meningitis" respectively supported by CRDF Global. RePORT-China was funded locally from the Innovation Alliance on TB Diagnosis and Treatment (Beijing) about $94,000.
The 7 sites participating in RePORT China included Beijing Chest Hospital, Changsha Central Hospital, The Third People's Hospital of Zhenjiang, Fuzhou Pulmonary Hospital, Tianjin Haihe Hospital, Suzhou Fifth People Hospital and Jingzhou Chest Hospital.
For a more comprehensive and up to date research bibliography visit our PubMed bibliography here.
For regional journal publications, please click here.